Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: Gynecol Oncol. 2009 Jul 31;115(1):112–120. doi: 10.1016/j.ygyno.2009.06.031

Figure 3.

Figure 3

Protein array from the assessment of immunoreactivity of patient sera. Panel A presents the array layout. Panel B shows 3 representative dot blots using sera from normal female controls. Panel C presents 3 representative dot blots using sera from patients with benign ovarian disease, while Panel D shows 3 representative dot blots using sera from ovarian cancer patients.